{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:42:21Z","timestamp":1791013341746,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>We present the case of a 51-year-old male with known congestive heart failure and acute myocarditis who presented to the emergency department (ED) with swollen testicles and urinary symptoms two weeks after the initiation of sodium glucose cotransporter 2 (SGLT2) inhibitor treatment. Abdominal and pelvic computed tomography (CT) scan was consistent with the diagnosis of Fournier\u2019s gangrene (FG). Intravenous antibiotics were administered and surgical exploratory intervention and excision of necrotic tissue were performed, stopping the evolution of necrotizing fasciitis. FG, a reported adverse event, may rarely occur when SGLT2 inhibitors are administered in patients with diabetes. To our knowledge, there have been no reported cases of FG in Romania since SLGT2 inhibitors were approved. The distinguishing feature of this case is that the patient was not diabetic, which emphasizes that patients without diabetes who are treated for heart failure with SGLT2 inhibitors may also be at risk of developing genitourinary infections. The association of predisposing factors may have contributed to the development of FG in this case and even though the benefits of SGLT2 inhibitors outweigh the risks, serious adverse events need to be voluntarily reported in order to intervene promptly, verify the relationship, and minimize the risk of bias.<\/jats:p>","DOI":"10.3390\/medicina60050837","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:26:27Z","timestamp":1716261987000},"page":"837","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fournier\u2019s Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors"],"prefix":"10.3390","volume":"60","author":[{"given":"Ioana-Maria","family":"Suciu","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Grelu\u0219","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, \u201cVasile Goldi\u0219\u201d Western University of Arad, Str. Liviu Rebreanu 86, 310045 Arad, Romania"},{"name":"Arad County Emergency Clinical Hospital, Str. Andreny Karoly nr. 2\u20134, 310037 Arad, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina-Ramona","family":"Cozlac","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"},{"name":"Cardiology Department, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timi\u0219oara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases Timi\u0219oara\u2014IBCV-TIM, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan-Simion","family":"Suciu","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Stoica","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"},{"name":"Cardiology Department, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timi\u0219oara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases Timi\u0219oara\u2014IBCV-TIM, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Luca","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"},{"name":"Cardiology Department, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin-Tudor","family":"Luca","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"},{"name":"Cardiology Department, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timi\u0219oara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases Timi\u0219oara\u2014IBCV-TIM, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-6779","authenticated-orcid":false,"given":"Dan-Ion","family":"Gai\u021b\u0103","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular Diseases Timi\u0219oara, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"},{"name":"Cardiology Department, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timi\u0219oara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases Timi\u0219oara\u2014IBCV-TIM, 13A Gheorghe Adam Street, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Xu, J., Hirai, T., Koya, D., and Kitada, M. (2021). Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010137"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.34067\/KID.0000472021","article-title":"Lower Urinary Tract Symptoms Should Be Queried When Initiating Sodium Glucose Co-Transporter 2 Inhibitors","volume":"2","author":"Krepostman","year":"2021","journal-title":"Kidney360"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/ndt\/gfz033","article-title":"Sodium glucose co-transporter 2 inhibition: A new avenue to protect the kidney","volume":"34","author":"Heerspink","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","unstructured":"Padda, I.S., Mahtani, A.U., and Parmar, M. (2024). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_5","unstructured":"Leslie, S.W., Rad, J., and Foreman, J. (Fournier Gangrene, 2024). Fournier Gangrene."},{"key":"ref_6","first-page":"e27773","article-title":"Fournier\u2019s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy","volume":"14","author":"Chowdhury","year":"2022","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/iwj.12812","article-title":"Prognostic factors and treatment outcomes for patients with Fournier\u2019s gangrene: A retrospective study","volume":"14","author":"Hong","year":"2017","journal-title":"Int. Wound J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier Gangrene Associated with Sodium\u2013Glucose Cotransporter-2 Inhibitors","volume":"170","author":"Chamberlain","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_9","first-page":"e29264","article-title":"A Rare but Life-Threatening Case of Fournier\u2019s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin","volume":"14","author":"Jahir","year":"2022","journal-title":"Cureus"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e237784","DOI":"10.1136\/bcr-2020-237784","article-title":"Fournier\u2019s gangrene with dapagliflozin in a rural hospital: A case report","volume":"14","author":"Elbeddini","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.eucr.2021.101834","article-title":"A case of Fournier\u2019s gangrene following a large-volume hydrocelectomy in a diabetic patient managed with SGLT-2 inhibitor therapy","volume":"39","author":"Vargo","year":"2021","journal-title":"Urol. Case Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.3393\/ac.2020.06.22","article-title":"Fournier Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Case Report","volume":"37","author":"Moon","year":"2021","journal-title":"Ann. Coloproctol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/ner.13385","article-title":"Abstracts from the North. American Neuromodulation Society\u2019s 2021, Virtual Meeting, 15\u201316 January 2021","volume":"24","author":"Newton","year":"2021","journal-title":"Neuromodulation Technol. Neural Interface"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijscr.2020.11.100","article-title":"Fournier\u2019s gangrene under SGLT-2 inhibitor therapy: A literature review and case report","volume":"77","author":"Prytz","year":"2020","journal-title":"Int. J. Surg. Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e921536-1","DOI":"10.12659\/AJCR.921536","article-title":"Fournier\u2019s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications","volume":"21","author":"Kasbawala","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.endinu.2019.12.007","article-title":"Gangrena de Fournier e inhibidores de la SGLT2: A prop\u00f3sito de un caso","volume":"67","year":"2020","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e920115-1","DOI":"10.12659\/AJCR.920115","article-title":"A Case of Fournier\u2019s Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus","volume":"21","author":"Elbeddini","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40800-019-0105-8","article-title":"Fournier\u2019s Gangrene in a Patient with Type 2 Diabetes Mellitus Treated with Empagliflozin: A Case Report","volume":"6","author":"Nagano","year":"2019","journal-title":"Drug Saf. Case Rep."},{"key":"ref_19","first-page":"e5778","article-title":"Fournier\u2019s Gangrene Under Sodium-Glucose Cotransporter 2 Inhibitor Therapy as a Life-Threatening Adverse Event: A Case Report and Review of the Literature","volume":"11","author":"Rodler","year":"2019","journal-title":"Cureus"},{"key":"ref_20","first-page":"e5173","article-title":"Early Presentation of a Rare Complication of Sodium-Glucose Cotransporter-2 Inhibitors 10 Days After Initiation: Case Report and Literature Review","volume":"11","author":"Elshimy","year":"2019","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/1753-0407.12896","article-title":"Fournier\u2019s gangrene in a patient on dapagliflozin treatment for type 2 diabetes","volume":"11","author":"Onder","year":"2019","journal-title":"J. Diabetes."},{"key":"ref_22","first-page":"97","article-title":"Sodium-glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin and Fournier\u2019s gangrene: A life-threatening severe adverse outcome. Case report","volume":"35","author":"Omer","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dme.13508","article-title":"Fournier\u2019s gangrene in a man on empagliflozin for treatment of Type 2 diabetes","volume":"34","author":"Kumar","year":"2017","journal-title":"Diabet. Med."},{"key":"ref_24","unstructured":"Chi, W.C., and Lim-Tio, S. (2016, January 24\u201326). Fournier\u2019s syndrome: A life threatening complication of SGLT2 inhibition in poorly controlled diabetes mellitus. Proceedings of the Joint Annual Scientific Meeting of the Australian Diabetes Educators Association and Australian Diabetes Society, Gold Coast, Queensland, Australia."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000985","DOI":"10.1136\/bmjdrc-2019-000985","article-title":"Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier\u2019s gangrene","volume":"8","author":"Yang","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_26","unstructured":"U.S. Food and Drug Administration (2024, March 15). FDA Adverse Event Reporting System (FAERS) Public Dashboard, Available online: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-ad-verse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard."},{"key":"ref_27","unstructured":"U.S. Food and Drug Administration (FDA) (2024, March 12). FDA Warns Abour Rare Occurrences of a Serious Infection of the Genital Area with SGLT2 Inhibitors for Diabetes, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes."},{"key":"ref_28","unstructured":"U.S. Food and Drug Administration (2024, April 12). FDA Drug Safety Communication: FDA Removes Boxed Warning about Risk of Leg and Foot Amputations for the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2024, March 15). FDA Drug Safety Communication: FDA Drug Safety Communication: FDA Strengthens Kidney Warnings for Diabetes Medicines Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin."},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2024, March 15). FDA Drug Safety Communication: FDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Andreea, M.M., Surabhi, S., Razvan-Ionut, P., Lucia, C., Camelia, N., Emil, T., and Tiberiu, N.I. (2023). Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?. Medicina, 59.","DOI":"10.3390\/medicina59040742"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Di Martino, A., Albanese, G., Di Salvo, J., Epifani, R., Marfella, R., and Docimo, G. (2022). An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073651"},{"key":"ref_33","unstructured":"Sackitey, C., and Tozer, P. (2022). Anal Fistula and Abscess, Springer."},{"key":"ref_34","first-page":"29","article-title":"Fournier Gangrene: Description of 37 Cases and Analysis of Associated Health Care Costs","volume":"103","year":"2012","journal-title":"Actas Dermo-Sifiliogr"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.ekir.2024.02.1404","article-title":"Fournier\u2019s Gangrene in a Patient with CKD Without Diabetes Possibly Related to Sodium-Glucose Cotransporter 2 Inhibitor Therapy","volume":"9","author":"Heidegger","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101163","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: A meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/5\/837\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:45:09Z","timestamp":1760107509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/5\/837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["medicina60050837"],"URL":"https:\/\/doi.org\/10.3390\/medicina60050837","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}